



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



DNCA

Item No. 38554

CAS Registry No.: 2226561-66-4
Formal Name: 4-amino-N-[2,3-bis[(9Z)-9-octadecen-1-yloxy]propyl]-2-oxo-1(2H)-pyrimidineacetamide
MF: C₄₅H₈₂N₄O₄
FW: 743.2
Purity: ≥95%
Supplied as: A solution in ethanol
Storage: -20°C
Stability: ≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

DNCA is a neutral lipid that has been used in the generation of lipid nanoparticles (LNPs).¹ Intravenous administration of LNPs containing DNCA and encapsulating siRNA targeting *BRAF* containing a valine-to-glutamate substitution at position 600 (*BRAF*^{V600E}) reduce tumor *BRAF*^{V600E} expression and tumor weight and volume without reducing animal weight in an A375 melanoma mouse xenograft model. Intratumoral administration of LNPs containing DNCA and encapsulating cyclic di-GMP (Item No. 17144) decreases tumor volume, increase survival, and increase the ratio of tumor-associated cytotoxic/exhausted CD4⁺ and CD8⁺ T cells in an EO771 murine model of primary breast cancer with tumor rechallenge.²

References

1. Zhou, X., Pan, Y., Li, Z., *et al.* siRNA packaged with neutral cytidinyl/cationic/PEG lipids for enhanced antitumor efficiency and safety *in vitro* and *in vivo*. *ACS Appl. Bio Mater.* **3**(9), 6297-6309 (2020).
2. Yu, X., Yu, J., Dai, H., *et al.* Novel formulation of c-di-GMP with cytidinyl/cationic lipid reverses T cell exhaustion and activates stronger anti-tumor immunity. *Theranostics* **12**(15), 6723-6739 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM